Consensus statement for treatment protocols in pressurized intraperitoneal aerosol chemotherapy (PIPAC).

Détails

Ressource 1Télécharger: 10.1515_pp-2022-0102.pdf (1042.99 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_678E7F75FE91
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Consensus statement for treatment protocols in pressurized intraperitoneal aerosol chemotherapy (PIPAC).
Périodique
Pleura and peritoneum
Auteur⸱e⸱s
Sgarbura O., Eveno C., Alyami M., Bakrin N., Guiral D.C., Ceelen W., Delgadillo X., Dellinger T., Di Giorgio A., Kefleyesus A., Khomiakov V., Mortensen M.B., Murphy J., Pocard M., Reymond M., Robella M., Rovers K.P., So J., Somashekhar S.P., Tempfer C., Van der Speeten K., Villeneuve L., Yong W.P., Hübner M.
ISSN
2364-768X (Electronic)
ISSN-L
2364-768X
Statut éditorial
Publié
Date de publication
01/03/2022
Peer-reviewed
Oui
Volume
7
Numéro
1
Pages
1-7
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
Safe implementation and thorough evaluation of new treatments require prospective data monitoring and standardization of treatments. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a promising alternative for the treatment of patients with peritoneal disease with an increasing number of suggested drug regimens. The aim was to reach expert consensus on current PIPAC treatment protocols and to define the most important research topics.
The expert panel included the most active PIPAC centers, organizers of PIPAC courses and principal investigators of prospective studies on PIPAC. A comprehensive literature review served as base for a two-day hybrid consensus meeting which was accompanied by a modified three-round Delphi process. Consensus bar was set at 70% for combined (strong and weak) positive or negative votes according to GRADE. Research questions were prioritized from 0 to 10 (highest importance).
Twenty-two out of 26 invited experts completed the entire consensus process. Consensus was reached for 10/10 final questions. The combination of doxorubicin (2.1 mg/m <sup>2</sup> ) and cisplatin (10.5 mg/m <sup>2</sup> ) was endorsed by 20/22 experts (90.9%). 16/22 (72.7%) supported oxaliplatin at 120 with potential reduction to 90 mg/m <sup>2</sup> (frail patients), and 77.2% suggested PIPAC-Ox in combination with 5-FU. Mitomycin-C and Nab-paclitaxel were favoured as alternative regimens. The most important research questions concerned PIPAC conditions (n=3), standard (n=4) and alternative regimens (n=5) and efficacy of PIPAC treatment (n=2); 8/14 were given a priority of ≥8/10.
The current consensus should help to limit heterogeneity of treatment protocols but underlines the utmost importance of further research.
Mots-clé
cisplatindoxorubicinoxaliplatinperitoneal metastasisPIPACstandardisationtreatment protocol, PIPAC, cisplatin, doxorubicin, oxaliplatin, peritoneal metastasis, standardisation, treatment protocol
Pubmed
Web of science
Open Access
Oui
Création de la notice
07/03/2022 16:48
Dernière modification de la notice
21/11/2022 8:23
Données d'usage